You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Middleton M, Aroldi F, Sacco J, et al
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0422